Data from 2 mothers indicate that the amount in milk is low, and no adverse effects were seen in infants who were exclusively breastfed during maternal tofacitinib use. Until more data become available, tofacitinib should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Expert opinion considers breastfeeding to be unadvisable during tofacitinib use.[1-3] The manufacturer and an expert panel recommend that breastfeeding be discontinued during tofacitinib therapy and for 18 hours after the last dose of the immediate-release product or 36 hours after the last dose of the sustained-release product.[4]
来自2位母亲的数据表明，母乳中的药物含量较低，在母亲使用托法替布期间纯母乳喂养的婴儿未出现不良反应。在获得更多数据之前，母乳喂养期间应谨慎使用托法替布，尤其是在喂养新生儿或早产儿期间。专家意见认为，使用托法替布期间不建议母乳喂养。[1-3]制造商和一个专家小组建议，在托法替布治疗期间以及最后一剂速释产品后18小时或最后一剂缓释产品后36小时内应停止母乳喂养。[4]
